1. Boehringer Ingelheim Pharmaceuticals, Inc. (2014) PRADAXA (dabigatran extexilate mesylate) package insert. Ridgefield, CT
2. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, the RE-LY Steering Committee and Investigators (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151
3. Huisman MV, Lip GY, Diener HC, Brueckmann M, van Ryn J, Clemens A (2012) Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 107:838–847
4. The United States Food and Drug Administration (2014) FDA drug safety communication: FDA study of Medicare patients finds risks lower for stroke and death but higher for gastrointestinal bleeding with Pradaxa (dabigatran) compared to warfarin. http://www.fda.gov/Drugs/DrugSafety/ucm396470.htm . Accessed 1 Dec 2014
5. Institute for Safe Medication Practices QuarterWatch (2013) Monitoring FDA Med-Watch reports: update on anticoagulants. www.ismp.org/quarterwatch/pdfs/2012Q2.pdf . Accessed 1 Dec 2014